Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration
Abstract Mavacamten is a selective, allosteric, reversible cardiac myosin inhibitor that has been developed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). A population pharmacokinetic (PopPK) model was developed to characterize mavacamten pharmacokinetics...
Guardat en:
| Autors principals: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2024-09-01
|
| Col·lecció: | CPT: Pharmacometrics & Systems Pharmacology |
| Accés en línia: | https://doi.org/10.1002/psp4.13197 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|